MedPlus Health IPO Date, Price, GMP & More.

Medplus Health IPO
Rate this post

MedPlus Health Services was established in 2006 by Gangadi Madhukar Reddy. The company offers a wide range of products in pharma, healthcare and wellbeing items. Their portfolio incorporates clinical gear, medicines, test packs, nutrients alongside FMCG items. The FMCG items include child care items, sanitisers, cleansers, toiletries, and many more. MedPlus being the pharma retailing chain is the first to offer an omnichannel deals network. The core operation of the company is of retail business. Gangadi Madhukar Reddy is currently serving as the Managing Director and the CEO of the Company. Grab all the information about Medplus Health IPO here.

The focus of the company is on making itself a trusted pharmacy retail brand. Their aim is to provides genuine medicines. They also focus on providing stronger value to customers by reducing supply chain inefficiencies through technology.


  • Prepayment of all the loans of the Company. It will be availed on a consolidated basis. 
  • To meet corporate targets. 
  • To fund the working capital requirement.


  • The second-largest pharmacy retailer in India. 
  • The company has an Established Brand and Value Proposition to Customers.
  • Focus on the Development in business operation. It will be done by utilizing a Distinct Cluster-based and Replicable Retail outlet Unit Expansion Strategy.
  • The Omni-channel proposition been upgraded with a high-density supply chain. 
  • The company have Technology-driven processes and a lean pricing framework system.
  • MedPlus has a Board of Directors and senior management team which is very capable, highly innovative, educated and well qualified.


Pharmacy retail outlet MedPlus filed its DRHP to float its IPO in the market. Currently, the firm is waiting for the approval of SEBI to launch an IPO of Rs. 1639 crores. The IPO Offer is divided in two segments. It comprises fresh issue equity shares of Rs. 600 crores. The IPO offer also includes an OFS of up to Rs. 1038.71 crores. 

The OFS will comprise of:

Equity shares by PI Opportunities Fund – I  Rs.500 crores
Equity shares by Lone Furrow Investments  Rs.450 crores  
Equity shares from various stakeholdersRs.88.71 lakh

The funds that will be raised by the company from the IPO will be used to fund the working capital requirements of MedPlus’s subsidiary. The subsidiary of the MedPlus is Optival Health Services. Also, it plans to meet the general corporate purpose from proceedings of the IPO.

IPO Opening DateOctober 2021
IPO Closing DateOctober 2021
Issue TypeBook Building Type
Face ValueRs.2 / Equity share
IPO Price 
Market Lot 
Min Order Quantity 
Listing AtBSE, NSE
Issue SizeRs.1639 Crores
Fresh IssueRs. 600 Crores
Offer for SaleRs. 1039 Crores
Basis of Allotment DateOctober 2021
Initiation of RefundsOctober 2021
Credit of Shares to Demat AccountOctober 2021
IPO Listing DateOctober 2021
Basis of the Allotment% Of IPO Offer
Qualified Institutional Buyer50
Non-Institutional Investor15


  • Focus of the company in Increment of the brand value in the cities where the Company operates by carrying out designated showcasing and publicizing campaigns.
  • The Company’s focus is to grow its market share in the overall industry by strengthening its business in cities and developing in rural areas.
  • The Cost investment funds of the company will be acknowledged because of the working influence. It is been acquired in their production network and inventory administration.
  • The Company has a very organized and thorough shop opening cycle set up. It also has specialized operations and business advancement staff at the nearby city and state levels to assess and approve new store openings. 
  • MedPlus is India’s first pharmacy store to offer an omni-channel stage. Since 2015, the customers have had the alternative of visiting their retail stores or getting their items online using their site and Mobile Application. 
  • The Company is focusing on increasing its customer base in all its stores. 
  • MedPlus is also working on retaining its client’s ecosystems.
  • In the financial year 2020, they began focusing more heavily on digital sales. The Revenue obtained from their digital sales channel has increased over the previous two years. The Digital sales was 8.98% and 6.99% of their overall income. The digital sale played a key part in their business operations in financial years 2021 and 2020, respectively.
  • The potential within the Indian Healthcare Sector is also another boost to the company. The market of healthcare is predicted to reach $372 billion by 2022. It will contribute 3% to India’s GDP by 2022.
  • The Company is also focusing on developing its Omni-channel Platform with a Hyperlocal Delivery Model.
  • The company is also working to increase their Revenue. The company is also focusing on the expansion of Customer Wallet Share. For this they used a strategy of  Continued Investment in Technology Infrastructure along with Expansion into Adjacent Healthcare Vertical.
  • It is also focusing on Increasing Operating Efficiency and Enhance Supply Chain Management to Drive Profitability.


  • The effect of COVID-19 on their business in the coming years is obscure and can’t be estimated. 
  • Changes in doctor prescribed medication cost and business terms might contrarily affect their business. 
  • The organization, subsidiaries, promoters, and directors are completely associated with progressing legal procedures. Any negative decision in any of these processes might hurt their Company.
  • The Company’s financial stability might be hurt if it didn’t effectively manage inventory and forecast demand. 
  • They might be defenseless against cyber-attacks and information technology system failures. 
  • The Company is exposed to the perils that accompany venturing into new business sectors. 
  • Representative bad conduct or mistakes that are hard to find may cause harm to the business. 
  • The Company’s business model is such that it relies on the use of physician-recommended prescriptions, and their brand value and non-exclusive medications might detrimentally affect their margins and sales, leading to the loss in the business.
  • The company have engaged in related party transactions in the past and may do so again in the future.
  • The company has a negative impact due to their financial agreements which states that their lenders have put some restrictive limitations on them.


Basic and Diluted Earnings Per Share

Financial PeriodBasic EPS (in INR)Diluted EPS (in INR)
Financial Year 20216.135.88
Financial Year 20200.210.20
Financial Year 20191.151.10
ParticularsFor the year/period ended ( in Cr.)
Total Assets1,565.661,348.70958.71 
Total Revenue3,090.812,887.892,284.94 
Profit After Tax63.111.7911.92 
  • MedPlus Health Services is a major player in this business vertical, operating on strong financials. 
  • In March 2021, MedPlus had total assets of worth Rs. 5484.24 million. It also reported an increase in its revenue from Rs. Six hundred thirty million in FY2019-20 to Rs.704 million in FY2020-21.
  • Recently MedPlus received round of funding from various institutions. The funding was about $13.7 million in February 2021.
  • The Company started from 48 stores. Mostly all the stores were in Hyderabad at its inception. Currently, it is India’s second-largest pharmacy retail network. The Company has an alliance with over 2,000 stores. These stores are spread across various states of India.
  • The major operation of their business and the revenue comes from Chennai, Bangalore, Hyderabad, and Kolkata. In FY21, these cities contributed around 88% of their income.
  • The Company is focusing on scaling up its number of store operations. In Hyderabad and Kolkata, their stores increased from 141 to 309 in FY21. In Bangalore, the no of stores under their business operation increased from 110 to 331. They also increased their store operation in Maharashtra and Odisha.
  • MedPlus was the second-largest pharmacy retailer in India. The parameters of the consideration are revenue from operations and the number of stores as in FY21. 
   Core EBITDA Margin (%)7.064.6651.59
   EBIT Margin (%)4.892.6584.15
   Pre-Tax Margin (%)3.101.02202.95
   PAT Margin (%)2.060.063190.19
   Cash Profit Margin (%)4.932.6784.83
   ROA (%)4.450.182319.01
   ROE (%)19.380.593184.72
   ROCE (%)20.0114.3439.58
   Asset Turnover (x)2.162.94-26.48
   Net Sales Growth (%)6.9226.31-73.69
   Core EBITDA Growth (%)57.80126.54-54.33
   EBIT Growth (%)96.8944.56117.42
   PAT Growth (%)3417.89-91.423838.81
   EPS Growth (%)1423.37-91.421657.02


The promoters of the company are:

  • Gangadi Madhukar Reddy
  • Agilemed Investments Private Limited
  • Lone Furrow Investments Private Limited
Pre-Issue Share Holding96.52%
Post Issue Share Holding


MedPlus Health Services Limited

707, 7th Floor, 5-9-13, Taramandal Commercial Complex,

Saifabad, Hyderabad 500 004, Telangana, India

Tel: +91 040 6724 6724




KFin Technologies Private Limited

Selenium, Tower B, Plot No- 31 and 32,

 Financial District, Nanakramguda,

 Serilingampally, Hyderabad, Rangareedi 500 032,

 Telangana, India

 Tel: +91 40 6716 2222/ 180034 54001




  • Credit Suisse Securities (India) Private Limited
  • Axis Capital Limited
  • Edelweiss Financial Services Limited
  • Nomura Financial Advisory and Securities (India) Private Limited



Please enter your comment!
Please enter your name here